Home News Equity raising

Alibaba Health raises $1.78 billion in Hong Kong's biggest secondary share sale in 5 years

Reuters
Reuters8/5/2020 09:58 AM GMT+08  • 1 min read
Alibaba Health raises $1.78 billion in Hong Kong's biggest secondary share sale in 5 years
Alibaba Health Information Technology has raised nearly $1.78 billion in Hong Kong’s largest follow-on share sale in five years.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Chinese healthcare services firm Alibaba Health Information Technology (0241.HK) has raised nearly US$1.3 billion ($1.78 billion) in Hong Kong’s largest follow-on share sale in five years, according to a statement from the company on Wednesday.

The company will issue 499 million new shares priced at HK$20.05 ($3.55) apiece, an 8% discount to the stock’s HK$21.80 closing price on the Hong Kong exchange on Tuesday.

The final price was at the low end of the flagged HK$20.05 to HK$20.50 range when the deal was launched earlier on Tuesday.

Alibaba Health, an arm of internet retail giant Alibaba Group (BABA.N), said the cash would be used to develop the company’s pharmaceutical e-commerce business, which has benefited from the growth of the online service sector during the coronavirus pandemic this year.

The transaction was the largest follow-on share sale on the Hong Kong Stock Exchange since 2015, and the biggest ever health care deal, according to a term sheet reviewed by Reuters.

The size of the deal was increased by 25% during the institutional bookbuild overnight following high demand from investors.

×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.